SELLAS Life Sciences Group, Inc. (SLS) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 43 days, typically, give or take 17 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q2 FY2026Tue, Aug 11, 2026after close 42 8-K
Q1 FY2026Tue, May 12, 2026after close 42 8-K
Q4 FY2025Thu, Mar 19, 2026after close 78 8-K
Q3 FY2025Wed, Nov 12, 2025after close 43 8-K
Q2 FY2025Tue, Aug 12, 2025after close 43 8-K
Q1 FY2025Tue, May 13, 2025after close 43 8-K
Q4 FY2024Thu, Mar 20, 2025after close 79 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 - - $134.7 Million in Cash and Cash Equivalents as of September 30, 2026 - NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company" exhibit
Q3 FY2026 "In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter." exhibit
Q3 FY2026 "In October 2026, the Company announced the required pre-specified 80 th event occurred, triggering the customary database lock, blinded data review procedures before statistical analysis, unblinding, and disclosure of topline results, which the Company expects to report this month." exhibit
Q3 FY2026 "Preliminary topline data is expected in Q4 2026." exhibit
Q2 FY2026 "Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - – 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 – – Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - N" exhibit
Q2 FY2026 "At the same time, we are making meaningful progress with SLS009 in our ongoing Phase 2 frontline AML study, where dosing continues and enrollment is tracking ahead of industry standards, with topline data expected in the fourth quarter of 2026." exhibit
Q2 FY2026 "Topline data expected in Q4 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SLS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SLS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SLS earnings date badge

HTML

<a href="https://veritasdata.dev/company/SLS/"><img src="https://veritasdata.dev/embed/SLS.svg" alt="SLS earnings date" width="240" height="56"></a>

Markdown

[![SLS earnings date](https://veritasdata.dev/embed/SLS.svg)](https://veritasdata.dev/company/SLS/)

Script

<script async src="https://veritasdata.dev/embed/SLS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SLS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.